Bavarian Nordic Q2 Revenue Surges, 2026 Outlook Upgraded
Bavarian Nordic posted a strong Q2 2026 with revenue about 2.03 billion DKK and EBITDA of roughly 925 million, lifting full-year guidance to around 5.7 billion DKK and targeting an EBITDA margin near 30%. The firm highlighted record Travel Health revenue, robust demand for rabies and chikungunya vaccines, a new 750 million DKK share buy-back, and updated Public Preparedness outlook alongside a revised Vimkunya sales view for 2026.